The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design

Fred Andersen, Matti Viitanen, Dag S Halvorsen, Bjørn Straume, Tom Wilsgaard, Torgeir A Engstad, Fred Andersen, Matti Viitanen, Dag S Halvorsen, Bjørn Straume, Tom Wilsgaard, Torgeir A Engstad

Abstract

Background: Progressive neurodegeneration in Alzheimer's disease (AD) induces cognitive deterioration, and there is controversy regarding the optimal treatment strategy in early AD. Stimulation therapy, including physical exercise and cholinesterase inhibitors are both reported to postpone cognitive deterioration in separate studies. We aimed to study the effect of stimulation therapy and the additional effect of donepezil on cognitive function in early AD.

Design: A two-by-two factorial trial comprising stimulation therapy for one year compared to standard care to which a randomized double-blinded placebo controlled trial with donepezil was added.

Setting: Nine rural municipalities in Northern Norway.

Participants: 187 participants 65 years and older with a recent diagnosis of mild or moderate AD were included in the study of which 146 completed a one-year follow-up.

Interventions: In five municipalities the participants received stimulation therapy whereas participants in four received standard care. All participants were randomised double-blindly to donepezil or placebo and tested with three different cognitive tests four times during the one-year study period.

Main outcome: Changes in MMSE sum score.Secondary outcome: Changes in ADAS-Cog and Clock Drawing Test.

Results: MMSE scores remained unchanged amongst AD participants receiving stimulation therapy and those receiving standard care. The results were consistent for ADAS-Cog and Clock Drawing Test. No time trend differences were found during one-year follow-up between groups receiving stimulation therapy versus standard care or between donepezil versus placebo.

Conclusion: In rural AD patients non-pharmacological and pharmacological therapy did not improve outcome compared with standard care but all groups retained cognitive function during one year follow-up. Other studies are needed to confirm these results.

Trial registration: ClinicalTrials.gov (Identifier: NCT00443014). EudraCT database (no 2004-002613-37).

Figures

Figure 1
Figure 1
Flowchart of dropouts during follow-up.
Figure 2
Figure 2
Flowchart of the study design and sample size divided on subgroups.

References

    1. Minati L, Edginton T, Bruzzone MG, Giaccone G. Current concepts in Alzheimer's disease: a multidisciplinary review. Am J Alzheimers Dis Other Demen. 2009;24(Suppl 2):95–121.
    1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet. 2011;377:1019–1031. doi: 10.1016/S0140-6736(10)61349-9.
    1. Golden J, Lawlor B. Treatment of dementia in the community. BMJ. 2006;333:1184–1185. doi: 10.1136/bmj.39051.484421.80.
    1. Clare L, Woods RT, Moniz Cook ED, Orrell M, Spector A. Cognitive rehabilitation and cognitive training for early-stage Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev. 2003;4:CD003260.
    1. Heyn P, Abreu BC, Ottenbacher KJ. The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil. 2004;85:1694–1704. doi: 10.1016/j.apmr.2004.03.019.
    1. Graff MJ, Vernooij-Dassen MJ, Thijssen M, Dekker J, Hoefnagels WH, Rikkert MG. Community based occupational therapy for patients with dementia and their care givers: randomised controlled trial. BMJ. 2006;333:1196. doi: 10.1136/.
    1. Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease. Cochrane Database Syst Rev. 2000;4:CD001190.
    1. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M. et al.Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379–397.
    1. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289:210–216. doi: 10.1001/jama.289.2.210.
    1. Requena C, Maestu F, Campo P, Fernandez A, Ortiz T. Effects of cholinergic drugs cognitive training on dementia: 2-year follow-up. Dement Geriatr Cogn Disord. 2006;22:339–345. doi: 10.1159/000095600.
    1. Matsuda O. Cognitive stimulation therapy for Alzheimer's disease: the effect of cognitive stimulation therapy on the progression of mild Alzheimer's disease in patients treated with donepezil. Int Psychogeriatr. 2007;19:241–252. doi: 10.1017/S1041610206004194.
    1. Chapman SB, Weiner MF, Rackley A, Hynan LS, Zientz J. Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezil. J Speech Lang Hear Res. 2004;47:1149–1163. doi: 10.1044/1092-4388(2004/085).
    1. Andersen F, Engstad T, Straume B, Viitanen M, Halvorsen DS, Hykkerud S, Sjøbrernd K. Recruitment methods in Alzheimer's disease research: general practice versus population based screening by mail. BMC Med Res Methodol. 2010;10:35–42. doi: 10.1186/1471-2288-10-35.
    1. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198. doi: 10.1016/0022-3956(75)90026-6.
    1. Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med. 1989;19:1015–1022. doi: 10.1017/S0033291700005742.
    1. Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA. et al.Clock drawing in Alzheimer's disease. A novel measure of dementia severity. J Am Geriatr Soc. 1989;37:725–729.
    1. Dratcu L, da Costa RL, Calil HM. Depression assessment in Brazil. The first application of the Montgomery-Asberg Depression Rating Scale. Br J Psychiatry. 1987;150:797–800. doi: 10.1192/bjp.150.6.797.
    1. Bebbington P. Welcome to ICD-10. Soc Psychiatry Psychiatr Epidemiol. 1992;27:255–257.
    1. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J. et al.Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734–746. doi: 10.1016/S1474-4422(07)70178-3.
    1. Burch EA, Andrews SR. Comparison of two cognitive rating scales in medically ill patients. Int J Psychiatry Med. 1987;17:193–200. doi: 10.2190/GCVN-D2LJ-APH3-KN0K.
    1. Stone SP, Ali B, Auberleek I, Thompsell A, Young A. The Barthel index in clinical practice: use on a rehabilitation ward for elderly people. J R Coll Physicians Lond. 1994;28:419–423.
    1. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–2314. doi: 10.1212/WNL.44.12.2308.
    1. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T. Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement. 2010;6:39–53. doi: 10.1016/j.jalz.2009.05.665.
    1. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E. et al.A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994;151:390–396.
    1. Spector A, Thorgrimsen L, Woods B, Royan L, Davies S, Butterworth M, Orrell M. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial. Br J Psychiatry. 2003;183:248–254. doi: 10.1192/bjp.183.3.248.
    1. Metitieri T, Zanetti O, Geroldi C, Frisoni GB, De LD, Dello BM. et al.Reality orientation therapy to delay outcomes of progression in patients with dementia. A retrospective study. Clin Rehabil. 2001;15:471–478.
    1. Olazaran J, Reisberg B, Clare L, Cruz I, Pena-Casanova J, Del ST. et al.Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. Dement Geriatr Cogn Disord. 2010;30:161–178. doi: 10.1159/000316119.
    1. Colagiuri B. Participant expectancies in double-blind randomized placebo-controlled trials: potential limitations to trial validity. Clin Trials. 2010;7:246–255. doi: 10.1177/1740774510367916.
    1. Wickstrom G, Bendix T. The "Hawthorne effect"–what did the original Hawthorne studies actually show? Scand J Work Environ Health. 2000;26:363–367. doi: 10.5271/sjweh.555.
    1. McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P. The Hawthorne Effect: a randomised controlled trial. BMC Medical Research Methodology. 2006;7:30–37.
    1. Benedetti F, Carlino E, Pollo A. How placebos change the patient's brain. Neuropsychopharmacology. 2011;36:339–354. doi: 10.1038/npp.2010.81.
    1. Dumitriu A, Popescu BO. Placebo effects in neurological diseases. J Med Life. 2010;3:114–121.
    1. Andersen F, Viitanen M, Halvorsen DS, Straume B, Engstad TA. Co-morbidity and drug treatment in Alzheimer`s disease. A cross sectional study of participants in the Dementia study in Northern Norway. BMC Geriatric. 2011;11:58–65. doi: 10.1186/1471-2318-11-58.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅